Comparison of Hyaluronic Acid, TheraCal, and Mineral Trioxide Aggregate as Pulpotomy Agents in Primary Molars
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age4-8
SponsorAl-Azhar University
About this trial
This randomized clinical trial aims to evaluation the clinical and radiographic outcomes of hyaluronic acid, TheraCal, and Mineral Trioxide Aggregate (MTA) when used as pulpotomy agents in primary molars.
The main question it aims to answer is:
In children with restorable mandibular second primary molars requiring pulpotomy, does the use of hyaluronic acid or TheraCal LC, compared to MTA, result in improved clinical and radiographic success rates over a 12-month follow-up period?
Eligibility criteria
Qualifiers
Age 4-8 years,
Co-operative patient
At least one restorable mandibular second primary molars with deep carious lesions requiring pulpotomy.
Absence of gingival swelling or sinus tract.
Disqualifiers
Swelling, sinus tract, or fistula.
Spontaneous pain.
Necrotic pulp, pathological mobility.
Cases require for general anesthesia.
Trial design
Treatments tested in this trial
- Hyaluronic Acid (HA)
- TheraCal
- Mineral Trioxide Aggregate
Treatment groups
66 Participants
are divided into 3 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov